Their results show that FNDC4 can improve insulin resistance by inhibiting inflammation and ER stress through the AMPK/HO-1 mediated pathway, suggesting that FNDC4 may be a new therapeutic agent for insulin resistance and T2D (Fig. 4). The gene discussed is HMOX1; the disease is Insulin resistance.